<DOC>
	<DOCNO>NCT01285310</DOCNO>
	<brief_summary>The purpose study determine whether Apremilast safe effective treatment patient rheumatoid arthritis , specifically improve sign symptom rheumatoid arthritis ( tender swollen joint , pain , physical function structure ) treat patient inadequate response Methotrexate .</brief_summary>
	<brief_title>Study Apremilast Evaluate Safety Effectiveness Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Must document diagnosis Rheumatoid Arthritis ( 1987 American College Rheumatology Criteria ) onset signs/symptoms disease ≥ 4 month duration randomization . Must receive treatment outpatient basis . Must active disease despite current methotrexate treatment define : ≥ 6 swollen joint ( 66 swell joint count ) AND ≥ 6 tender joint ( 68 tender joint count ) . Must meet least one four lab requirement : High Sensitivity CReactive Protein ( hsCRP ) ≥ 10 mg/L Erythrocyte Sedimentation Rate ( ESR ) &gt; 28 mm first 1 hour Positive Rheumatoid Factor ( RF ) Positive Anticyclic Citrullinated Peptide ( antiCCP ) antibody For participant participate Magnetic Resonance Imaging ( MRI ) assessment : • Must Rheumatoid Arthritis joint involvement , assess swollen joint count : 1 ) least two Metacarpophalangeal ( MCP ) swell joint hand , 2 ) least one swollen Metacarpophalangeal ( MCP ) joint swell wrist hand . Must treat methotrexate least 4 month prior randomization , must stable dose . Participants require maintain stable dose Week 52 study . Oral folate ( folic acid ) supplementation require minimum dose 5 mg/week , instead leucovorin may use 10 mg/week orally . • Nonsteroidal antiinflammatory drug ( NSAIDs ) pain medication allow , however , must stable regimen least 7 day prior randomization Week 52 study . Oral corticosteroid ( take ) allow , however , must stable dose prednisone ≤ 10 mg/day equivalent least 28 day prior randomization Week 52 study . Must meet follow laboratory criterion screen : White blood cell count ≥ 3000/mm^3 ( ≥ 3.0 x 10^9/L ) &lt; 14,000/mm^3 ( &lt; 14 x 10^9/L ) Platelet count ( ≥ 100,000/μL ( ( ≥ 100 x 10^9/L ) Serum creatinine ≤ 1.5 mg/dL ( ≤ 132.6 μmol/L ) Aspartate aminotransferase serum glutamic oxaloacetic transaminase ( AST/SGOT ) alanine aminotransferase serum glutamicpyruvic transaminase ( ALT/ SGPT ) ≤ 2 x upper limit normal ( ULN ) . If initial test show Aspartate aminotransferase ( AST ) alanine aminotransferase ( SLT ) 2 time upper limit normal ( ULN ) , one repeat test allow screening period . Total bilirubin ≤ 2 mg/dL ( ≤ 34 μmol/L ) . If initial test result &gt; 2 mg/dL , one repeat test allow screening period . Hemoglobin ≥ 9 g/dL ( ≥ 5.6 mmol/L ) Hemoglobin A1c ≤ 9.0 % Negative hepatitis B surface antigen Negative hepatitis C antibody Males engage activity conception possible must use protocol describe barrier contraception Investigational Product least 28 day last dose Investigational Product . Females childbearing potential ( FCBP ) must negative pregnancy test Screening Baseline . FCBP engage activity conception possible must use protocol describe contraception Investigational Product least 28 day take last dose Investigational Product . Major surgery ( include joint surgery ) within 8 week prior screen plan major surgery within 6 month follow randomization . Rheumatic autoimmune disease Rheumatoid Arthritis , include systemic lupus erythematosus , mixed connective tissue disease , scleroderma , polymyositis significant systemic involvement secondary Rheumatoid Arthritis ( eg , vasculitis , pulmonary fibrosis Felty syndrome ) . Sjögren syndrome secondary Rheumatoid Arthritis allowable . Functional Class IV define American College Rheumatology ( ACR ) Classification Functional Status Rheumatoid Arthritis . Prior history , current , inflammatory joint disease Rheumatoid Arthritis ( eg , gout , reactive arthritis , psoriatic arthritis , ankylose spondylitis , Lyme disease ) . Receiving treatment Diseasemodifying antirheumatic drug ( DMARDs ) ( methotrexate ) , include biologic Diseasemodifying antirheumatic drug ( DMARDs ) Previous use allow adequate washout prior randomization . Inadequate response treatment antitumor necrosis factor ( antiTNF ) agent . Patients terminate previous antitumor necrosis factor ( antiTNF ) treatment due cost safety reason , discomfort subcutaneous injection , may participate study adequate washout . Treatment investigational agent within four week ( five halflives investigational drug , whichever long ) screening . Previous treatment cell deplete therapy , include investigational agent . Treatment intravenous gamma globulin , plasmapheresis Prosorba® column within 6 month baseline . Intraarticular parenteral corticosteroid allow within 6 week prior randomization . Any previous treatment alkylating agent cyclophosphamide chlorambucil , total lymphoid irradiation . Pregnant woman nurse ( breast feeding ) mother . Evidence serious uncontrolled concomitant cardiovascular , nervous system , pulmonary ( include severe severe chronic obstructive pulmonary disease ) , renal , hepatic , endocrine ( include uncontrolled diabetes mellitus define Hemoglobin A1c &gt; 9.0 % ) gastrointestinal ( GI ) disease . Uncontrolled disease state , asthma , psoriasis inflammatory bowel disease , flare commonly treated oral parenteral corticosteroid . Known active current history recurrent bacterial , viral , fungal , mycobacterial infection ( include limit tuberculosis atypical mycobacterial disease , Hepatitis B C , herpes zoster , exclude onychomycosis ) major episode infection require hospitalization treatment IV oral antibiotic within 4 week screen . History positive Human Immunodeficiency Virus ( HIV ) , congenital acquire immunodeficiency ( eg , Common Variable Immunodeficiency Disease ) . History malignancy , include solid tumor hematologic malignancy ( except basal cell carcinoma skin excise cure ) . History alcohol , drug chemical abuse within 6 month prior screen . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . Any condition include presence laboratory abnormality , place subject unacceptable risk he/she participate study . Any condition investigator 's opinion would interfere significantly efficacy evaluation , include pain joint assessment ( eg , fibromyalgia ) . For Magnetic Resonance Imaging ( MRI ) Only : Receiving medication ( ) require medication ( ) study impact vascular flow ( eg , nitrate , calcium channel blocker , ergot contain drug ) day Magnetic Resonance Imaging ( MRI test investigator 's judgement subject hold back take medication day Magnetic Resonance Imaging ( MRI ) prior Magnetic Resonance Imaging ( MRI ) test . The subject continue take medication ( ) time Magnetic Resonance Imaging ( MRI ) test complete , clinically indicate schedule . Exclusions antihypertensive migraine medication determine discussion Sponsor . Unable undergo Magnetic Resonance Imaging ( MRI ) examination , include limited presence pacemaker , defibrillator , implanted device anterior interbody cage , aneurysm clip , pedicle screw , metal contain body ( eg , tattoos contain metallic pigment , metal eye metal grind [ eg , metal worker , etc ] ) , severe claustrophobia , contraindication Magnetic Resonance Imaging ( MRI ) per local imaging center guideline . Allergic adverse reaction gadolinium Estimated glomerular filtration rate ( eGFR ) 60 mL/min/1.73m2 ( base Modification Diet Renal Disease [ MDRD ] formula ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Rheumatoid , Arthritis</keyword>
</DOC>